Imunon, Inc. 8-K

What Happened
Imunon, Inc. announced on January 7, 2026 (8‑K filing) that interim Chief Financial Officer Kimberly Graper will resign effective January 14, 2026 to pursue another opportunity and that Jeffrey Church will be appointed interim Chief Financial Officer and principal accounting officer effective January 14, 2026. Ms. Graper’s departure is without disagreement with management. Mr. Church is a long‑time Imunon executive (joined July 2010) who retired from his executive roles effective June 1, 2024 and has been providing consulting services since May 2024.

Key Details

• Resignation: Kimberly Graper (Interim CFO) — resignation effective January 14, 2026; departure described as voluntary and without disagreement with management.
• Appointment: Jeffrey Church named interim Chief Financial Officer and principal accounting officer effective January 14, 2026.
• Consulting terms: Consulting Agreement (amended Jan 14, 2026) provides Mr. Church a $30,000 monthly retainer plus $250 per hour for services beyond 40 hours/month; the consulting period may be terminated on 10 business days’ notice.
• Background: Mr. Church served in multiple senior finance roles at Imunon since 2010 (including EVP & CFO) and previously held CFO positions at other biotech firms.

Why It Matters
A change in the company’s principal financial officer affects who is responsible for Imunon’s financial reporting and investor communications. Investors should note the immediate continuity: the new interim CFO, Jeffrey Church, has extensive prior experience at Imunon and in the biotech sector, and will serve under a short‑term consulting arrangement with disclosed compensation. This is a personnel and governance item (Item 5.02) rather than a change to financial results; monitor future filings for any further staffing updates or effects on financial reporting.